and claims 37-41 as dawn to a kit comprising (a) a capture reagent that binds a biomarker is Marker I (BCI) and (b) a container comprising at least one of the biomarkers.

Group 2. Claims 1-25, 26, 27-36, as drawn to a method of qualifying breast cancer in a subject comprising (a) measuring at least one biomarker in sample from a subject, and (b) correlating the measurement with breast cancer status, wherein the biomarker is Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X, Marker XI, Marker XII, Marker XIII, Marker XIV.

Group 3. Claims 37-41, as drawn to a kit comprising (a) a capture reagent that binds a biomarker is selected from the group consisting of Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X, Marker XI, Marker XII, Marker XIII, Marker XIV and (b) a container comprising at least one of the biomarkers.

Group 4. Claims 42-46, as drawn to a kit comprising (a) a first capture reagent th at binds at least one biomarker selected from the group consisting of Marker I (BCI), Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X, Marker XI, Marker XII, Marker XIII, Marker XIV, and (b) a second capture reagent that binds at least one of the biomarkers that is not bound by the first capture reagent.

Group 5. Claims 47-53, as drawn to a kit comprising (a) a first capture reagent that binds at least one biomarker selected from the group consisting of Marker I (BCI), Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X, Marker XI, Marker XII, Marker XIII, Marker XIV, and (b) instructions for using the capture reagent to detect the biomarker.

Group 6. Claims 54-56, as drawn to a kit comprising (a) a first capture reagent that binds at least one biomarker that binds to at least two biomarkers selected from the group consisting of selected from the group consisting of Marker I (BCI), Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X,

Marker XI, Marker XII, Marker XIII, Marker XIV, and (b) instructions for using the capture reagent to detect the biomarker.

Group 7. Claim 57, as drawn to a kit comprising (a) a plurality of capture reagents each of which has bound to it a different biomarker selected from the group consisting of Marker I (BCI), Marker II (BC2), Marker III (BC3), Marker IV, Marker V, Marker VI, Marker VII, Marker VIII, Marker IX, Marker X, Marker XI, Marker XII, Marker XIII, Marker XIV Applicant hereby provisionally elects claims Group 2 (Claims for continued examination.

Applicants hereby elect Group 2 (Claims 1-25, 26, and 27-36). The Examiner has further required multiple species elections to which the claims will be restricted if no generic claim is ultimately held allowable. Accordingly, Applicants elect: (i) managing treatment step of ordering more tests; (ii) breast cancer status of subject's risk of cancer; (iii) the known breast cancer marker of CA 15.3; (iv) substrate of a microtiter plate comprising biospecific affinity reagents; (v) measuring type of quantifying the amount of marker(s); (vi) biochip array type of a protein chip array; (vii) method of protein detection of immunoassay; and (viii) and Marker III (BC3).

Dated: June 5, 2007

Respectfully submitted,

By _____

Jonathan M. Sparks, Ph.D.
Registration No.: 53,624
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorneys/Agents For Applicant